65.49 - 69.47
15.52 - 95.21
Echofin Members Consensus
14:26 EDT MRNA Moderna CEO says vaccine won't be ready before election, FT reports The CEO of Moderna Therapeutics, one of the companies developing a coronavirus vaccine, said his company would not be able to apply for authorization until at least late November, Financial Times' Kiran Stacey and Hannah Kuchler report. Stephane Bancel told the Financial Times on Wednesday that Moderna would not be ready to seek emergency use authorization from the Food and Drug Administration before November 25 at the earliest.
Next Dividend Date
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
CEO: Stéphane Bancel
HQ: 200 Technology Square Cambridge, 02139 MA